Background: Presently, there are limited reports in the literature on
the post-operative (mid-term) clinical outcome for pure Aortic
Regurgitation (AR) following Transcatheter Aortic Valve Replacement
(TAVR). Methods: Between March 2014 and June 2019, a total of 134
high-risk patients with pure, symptomatic severe AR patients were
enrolled in the current study. The outcome was assessed according to the
VARC-2 criteria. Procedural results, clinical outcomes, and the
patients’ hemodynamics for a period of 1-year were analyzed. Results:
Patient mean was 73.1±6.4 years and 25.4% were female. The average STS
score was 9.8+5.3%. Procedural success was 97.1% (130/134), and the
device success rate was 96.3% (129/134). Five cases were converted to
open surgery, while two patients underwent valvular reinterventions
(surgical aortic valve replacement for thrombosis and increasing
paravalvular regurgitation). The mean aortic valve gradient was 10.2±4.1
mmHg, while the moderate and severe aortic regurgitation was 1.6% at 1
year. Paravalvular regurgitation was none/trivial in 79.8% and mild in
18.5%. The 1-year all-cause mortality rate was 7.4%. At 1-year, the
stroke incidence rate was 2.2%. And pacemaker was implanted in 8.9% of
the enrolled patients. Conclusions: In high-risk patients undergoing
transapical-TAVR for AR, the use of the J-Valve is safe and effective
TAVR should be considered as a reasonable option for high-risk patients
with pure AR.
A MULTIDISCIPLINARY, MULTIMODALITY, BUT MINIMALIST (3M) APPROACH TO TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT FACILITATES SAFE NEXT DAY DISCHARGE HOME IN HIGH RISK PATIENTS: 1 YEAR FOLLOW UP
